Skip to content

A single-arm, open-label, single-center study to evaluate the efficacy and safety of low-concentration sevoflurane in patients with learning disabilities

A single-arm, open-label, single-center study to evaluate the efficacy and safety of low-concentration sevoflurane in patients with learning disabilities

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126162
Enrollment
Unknown
Registered
2026-06-04
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Learning Disabilities

Interventions

Experimental group:The concentration of inhaled sevoflurane is 0.4-0.6 MAC, with an oxygen concentration of 50%, and the treatment duration is 2 hours.

Sponsors

Guangzhou Medical University Affiliated Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for specific learning disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). 2. Aged between 3 and 18 years (inclusive), right-handed, with no gender restriction. 3. Able to complete all assessments. 4. The subject's parent or legal guardian has adequate reading and comprehension skills to cooperate in completing the relevant assessment scales and follow-up visits. 5. The subject, parent, or legal guardian voluntarily participate in this study after signing written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of other neurodevelopmental disorders besides specific learning disorder (e.g., intellectual disability, communication disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, motor disorder, tic disorder, etc.). 2. Presence of serious physical illnesses or other systemic diseases (e.g., history of renal, hepatic, endocrine, or immune disorders, etc.). 3. Presence of metabolic disorders, neoplasms, infections, or organic neurological diseases. 4. Serum potassium or magnesium levels outside the normal range. 5. History of neuroleptic malignant syndrome or tardive dyskinesia. 6. Participation in another study within 30 days prior to the start of the current study and/or during the study period.

Design outcomes

Primary

MeasureTime frame
Wechsler Intelligence Scale for Children (WISC);

Secondary

MeasureTime frame
Learning Disabilities Screening Scale (PRS);Conners Child Behavior Rating Scale (CRS);Achenbach Child Behavior Checklist (CBCL);Academic Achievement Test (AAT);Learning Skills Diagnostic Test (LSDT);Clinical Global Impression-Severity;Clinical Global Impression-Improvement;Electroencephalogram;Functional Magnetic Resonance Imaging;

Countries

China

Contacts

Public ContactXingrong Song

Guangzhou Medical University Affiliated Women and Children's Medical Center

sxjess@126.com+86 139 2241 6303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026